Clinical Trial

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (Protocol I6T-MC-AMBG/LUCENT 2)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN.

Information

Principal Investigator Sriramanchandra M. Badiga, MD
Co-PI
Sponsor Eli Lilly and Company/USA
Type of Trial Interventional